Loading doses for costly cancer biologicals: Sound pharmacology or unnecessary extravagance?

European Journal of Cancer

Volumn 44, Issue 11, 2008, Pages 1488-1492

  Epstein, Richard J ^a   Cheung, Bernard M Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cost effectiveness; Health economics; Medical oncology; Pharmacokinetics

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CLOPIDOGREL; EPIDERMAL GROWTH FACTOR RECEPTOR; FULVESTRANT; IBANDRONIC ACID; LIDOCAINE; PERIFOSINE; PERTUZUMAB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TRASTUZUMAB; WARFARIN;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTHMA; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG METABOLISM; EPILEPSY; GENETIC DISORDER; GRAFT REJECTION; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; LOADING DRUG DOSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SKIN TOXICITY; STROKE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; HUMANS; NEOPLASMS;

EID: 46249101531     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.12.006     Document Type: Article

References (47)

1. Peck C.C., and Cross J.T. "Getting the dose right": facts, a blueprint, and encouragements. Clin Pharmacol Ther 82 1 (2007) 12-14
2. Park K., Verotta D., Gupta S.K., and Sheiner L.B. Use of a pharmacokinetic/pharmacodynamic model to design an optimal dose input profile. J Pharmacokinet Biopharm 26 4 (1998) 471-492
3. Minto C.F., Schnider T.W., Gregg K.M., Henthorn T.K., and Shafer S.L. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics. Anesthesiology 99 2 (2003) 324-333
4. Toutain P.L., and Bousquet-Melou A. Volumes of distribution. J Vet Pharmacol Ther 27 6 (2004) 441-453
5. Biondi-Zoccai G.G., Lotrionte M., Agostoni P., et al. Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression. Am Heart J 153 4 (2007) 587-593
6. Gurbel P.A., Bliden K.P., Hayes K.M., Yoho J.A., Herzog W.R., and Tantry U.S. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45 9 (2005) 1392-1396
7. Eckhoff C.D., Didomenico R.J., and Shapiro N.L. Initiating warfarin therapy: 5 mg versus 10 mg. Ann Pharmacother 38 12 (2004) 2115-2121
8. Stargel W.W., Shand D.G., Routledge P.A., Barchowsky A., and Wagner G.S. Clinical comparison of rapid infusion and multiple injection methods for lidocaine loading. Am Heart J 102 5 (1981) 872-876
9. Pea F., Brollo L., Viale P., Pavan F., and Furlanut M. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother 51 4 (2003) 971-975
10. Cornely O.A., Maertens J., Bresnik M., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44 10 (2007) 1289-1297
11. Hoang K.D., and Pollack Jr. C.V. Antibiotic use in the emergency department. IV: single-dose therapy and parenteral-loading dose therapy. J Emerg Med 14 5 (1996) 619-628
12. El-Sabrout R., Delaney V., Butt F., et al. Improved freedom from rejection after a loading dose of sirolimus. Transplantation 75 1 (2003) 86-90
13. Wilson J.T., Hojer B., and Rane A. Loading and conventional dose therapy with phenytoin in children: kinetic profile of parent drug and main metabolite in plasma. Clin Pharmacol Ther 20 1 (1976) 48-58
14. Simons F.E., Simons K.J., Shapiro G.G., Pierson W.E., and Bierman C.W. Pharmacokinetics of theophylline in acute asthma. J Med 9 1 (1978) 81-90
15. Schaller G., Fuchs I., Gonsch T., et al. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 25 22 (2007) 3246-3250
16. Baselga J., Carbonell X., and Castaneda-Soto N.J. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23 10 (2005) 2162-2171
17. Souglakos J., Kalykaki A., Vamvakas L., et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 18 2 (2007) 305-310
18. Cameron D., Fallon M., and Diel I. Ibandronate: its role in metastatic breast cancer. Oncologist 11 Suppl. 1 (2006) 27-33
19. Agus D.B., Sweeney C.J., Morris M.J., et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 25 6 (2007) 675-681
20. Leighl N.B., Dent S., Clemons M., Vandenberg T.A., Tozer R., Warr D.G., et al. A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat (2007)
21. Atkinson Jr. A.J., and Lalonde R.L. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview. Clin Pharmacol Ther 82 1 (2007) 3-6
22. Powles T.J., Coombes R.C., Smith I.E., Jones J.M., Ford H.T., and Gazet J.C. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet 1 8168 Pt 1 (1980) 580-582
23. Molckovsky A., Vijay S.M., Hopman W.M., Bryson P., Jeffrey J.F., and Biagi J.J. Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients. Int J Gynecol Cancer (2007)
24. Wood W.C., Budman D.R., Korzun A.H., et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. New Engl J Med 330 18 (1994) 1253-1259
25. Carlson R.W., and Wheatley K. High-dose chemotherapy and stem cell transplantation does not improve relapse-free or overall survival in women with high-risk breast cancer. Cancer Treat Rev 30 1 (2004) 131-137
26. Montemurro F., Rondon G., Ueno N.T., Munsell M., Gajewski J.L., and Champlin R.E. Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy. Bone Marrow Transplant 29 10 (2002) 861-866
27. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 344 11 (2001) 783-792
28. Epstein R.J. Maintenance therapy to suppress micrometastasis: the new challenge for adjuvant cancer treatment. Clin Cancer Res 11 15 (2005) 5337-5341
29. Blagosklonny M.V. Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle 4 12 (2005) 1693-1698
30. Prapotnich D., Fizazi K., Escudier B., Mombet A., Cathala N., and Vallancien G. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 43 3 (2003) 233-239 [discussion 239-240]
31. Fabian C., Sternson L., and Barnett M. Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer Treat Rep 64 6-7 (1980) 765-773
32. de Vos D., Slee P.H., Briggs R.J., and Stevenson D. Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels. Cancer Chemother Pharmacol 42 6 (1998) 512-514
33. Spooner D., Fairlamb D., and Fermont D. A multicentre trial to compare a loading dose regimen of tamoxifen ('Nolvadex') with conventional dosing in the treatment of advanced breast cancer. The British Tamoxifen Study Group. Clin Oncol (R Coll Radiol) 3 3 (1991) 133-136
34. Robertson J.F. Fulvestrant (Faslodex) how to make a good drug better. Oncologist 12 7 (2007) 774-784
35. Shull G.H. The "presence and absence" hypothesis. Am Nat 43 (1909) 410-419
36. Hamblett K.J., Senter P.D., Chace D.F., et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10 20 (2004) 7063-7070
37. Bateman D.N. Digoxin-specific antibody fragments: how much and when?. Toxicol Rev 23 3 (2004) 135-143
38. Harding J., and Burtness B. Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today (Barc) 41 2 (2005) 107-127
39. Lenz H.J., Van Cutsem E., Khambata-Ford S., et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24 30 (2006) 4914-4921
40. Bruno R., Washington C.B., Lu J.F., Lieberman G., Banken L., and Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56 4 (2005) 361-369
41. Duconge J., Castillo R., Crombet T., et al. Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody. Eur J Pharm Sci 21 2-3 (2004) 261-270
42. Duconge J., Fernandez-Sanchez E., and Alvarez D. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable?. Biopharm Drug Dispos 25 4 (2004) 177-186
43. Kocs D., and Fendrick A.M. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience. Am J Manag Care 9 5 (2003) 393-400 [quiz 401-402]
44. Niezen M.G., Stolk E.A., Steenhoek A., and Uyl-De Groot C.A. Inequalities in oncology care: Economic consequences of high cost drugs. Eur J Cancer 42 17 (2006) 2887-2892
45. Drummond M.F., and Mason A.R. European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Oncol 25 2 (2007) 191-195
46. Jack A. No cure no cost. Br Med J 335 (2007) 122-123
47. Powell J.R., and Gobburu J.V. Pharmacometrics at FDA: evolution and impact on decisions. Clin Pharmacol Ther 82 1 (2007) 97-102